Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor
Sign Up to like & getrecommendations! Published in 2022 at "Acta Neurochirurgica"
DOI: 10.1007/s00701-022-05109-w
Abstract: Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case… read more here.
Keywords: monotherapy; braf; posterior pituitary; mutated ttf ... See more keywords
TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Neurology and Neurosurgery"
DOI: 10.1016/j.clineuro.2020.106059
Abstract: Abstract Spindle cell oncocytoma (SCO) represents one of the four TTF-1 positive posterior pituitary tumors (PPTs) as defined by the World Health Organization in 2017. Due to the recurrent nature of these tumors, repeat interventions… read more here.
Keywords: braf v600e; braf; ttf positive; mutation ... See more keywords
Acinar Adenocarcinoma of Prostate with Predominant Ttf-1 Positive Intraductal Component.
Sign Up to like & getrecommendations! Published in 2017 at "Turk patoloji dergisi"
DOI: 10.5146/tjpath.2014.01253
Abstract: Intraductal carcinoma of prostate has been previously described in radical prostatectomies. It's rarely encountered in needle biopsies in the absence of infiltrative carcinoma. But, both histogenesis and nomenclature of the lesion is still controversial. Among… read more here.
Keywords: prostate; intraductal component; acinar adenocarcinoma; ttf positive ... See more keywords